62 results about "Drug specific IgE" patented technology

This invention provides methods for determining drug specificity, therapeutic index and effective doses for individual patients. According to the methods of the invention, graded levels of drug are applied to a biological sample or a patient. A plurality of cellular constituents are measured to determine the activity of the drug on a target pathway and at least one off-target pathway. A drug specificity is determined by comparing the target and off target activities of the drug. A therapeutic concentration (or dose) is defined as a concentration (or dose) of the drug that induces certain response in the target pathway. A toxic concentration (or dose) is defined as a concentration (or dose) of the drug that induces certain response in the off target pathway. Therapeutic index is the ratio of the toxic concentration over therapeutic concentration. Methods are also provided to determine an effective dose of a drug for a patient by measuring the activity of the drug on the particular patient.

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing folate receptor alpha (FRA) and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to FRA-expressing cells as well as in eliciting an immune-effector activity particularly on tumor cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer cells; and methods of treating cancer using the antibodies.

An astrocyte-specific drug carrier containing a retinoid derivative and/or a vitamin A analog as a constituent; a drug delivery method with the use of the same; a drug containing the same; and a therapeutic method with the use of the drug. By binding a drug carrier to a retinoid derivative such as vitamin A or a vitamin A analog or encapsulating the same in the drug carrier, a drug for therapeutic use can be delivered specifically to astrocytes. As a result, an astrocyte-related disease can be efficiently and effectively inhibited or prevented while minimizing side effects. As the drug inhibiting the activity or growth of astrocytes, for example, a siRNA against HSP47 which is a collagen-specific molecule chaperone may be encapsulated in the drug carrier. Thus, the secretion of type I to type IV collagens can be inhibited at the same time and, in its turn, fibrosis can be effectively inhibited.

A method for preparing both main label and warning label portions for a container useful in dispensing drugs by a pharmacist in which the main label portion contains specific drug or patient information and the warning label portion contains one or more warnings specific to the drug or patient information includes the steps of providing a backing sheet having the main label portion and the warning label portion releasably adhered thereto, printing the drug or patient information on the warning label during only one printing pass, and then affixing both the main label portion and the warning label portion to a drug container.

A transfer needle comprises: a liquid-specific member; and a medicament-specific member to be separably connected or joined to the liquid-specific member in a liquid-tight state. The liquid-specific member comprises: a liquid-specific hollow needle projecting toward the opposite side from the medicament-specific member. The medicament-specific member comprises: a medicament-specific hollow needle projecting toward the opposite side from the liquid-specific member and communicating with the liquid-specific hollow needle. A female lure is provided on at least one of the liquid-specific member and the medicament-specific member at a position opposing to the other. The female lure communicates with the one hollow needle and is separably connected with an injection needle connecting portion of a syringe in a liquid-tight state.

The invention relates to histone deacetylase (HDAC) biomarkers in multiple myeloma. Specifically, the biomarkers are drug specific, histone deacetylase (HDAC) or HDAC6 biomarker RNAs for multiple myeloma. The invention also relates to a kit for determining the treatment efficiency of a HDAC6 inhibitor, and a kit for identifying a histone deacetylase 6 (HDAC6) inhibitor. The invention further relates to a method for monitoring treatment efficiency of an HDAC inhibitor in a subject.

A gene-drug specific system for classifying individual genetic variants based on strength-of-evidence of clinical utility from published scientific and clinical data that support their effect on modifying drug response and behavior. This allows categorization of the genetic variants into evidence classes that have a wide range of uses such as pharmacogenomic molecular diagnostics and personalized medicine research designed to guide the clinical implementation of PGx. Furthermore, this information can be combined with a knowledgebase of drug-response phenotypes, a knowlegebase of specific drug-induced outcomes and individual patient diplotype information for a gene-drug combination into a programmed computer to output corresponding patient-specific predicted drug responses.

A device operable in a medication compliance system, wherein a patient has a patient-specific and medication-specific compliance schedule. The device includes a processor and memory; at least one long-range telemetry module, operatively connected to the processor, and providing connectivity between the device and remote networks, the at least one long-range telemetry module including at least one cellular radio; at least one short-range telemetry module, operatively connected to the processor, and providing connectivity between the device and local devices; and a display controlled by the processor, the display providing feedback from the medication compliance system, in accordance with a patient-specific and medication-specific compliance schedule.

Embodiments of the invention include a method of collecting and reporting quality of life data from a patient. A patient may participate in a collection of surveys during the course of disease treatment that are automatically tailored to the patient's disease state using multidimensional tools to generate quality of life metrics. Reports are generated from the aggregate data to aid in treatment of the patient by enhancing patient/healthcare provider communications, patient education and by giving the healthcare provider reports on quality of life metrics correlated to the prescribed treatments, comorbid diseases, disease specific and medication specific review of systems and patient compliance with the prescribed treatments. Further, data from multiple patients are aggregated for reports that can provide evaluations of the effect of prescribed treatments, reasons for patient non-compliance with prescribed treatments and the prevalence and effect of off-label use of medications.

This invention relates to the use of monoclonal and polyclonal antibodies that specifically bind to and have the ability in the alternative to become internalized by cells expressing endosialin and to induce an immune effector activity such as antibody-dependent cellular cytotoxicity. The antibodies are useful in specific delivery of pharmacologic agents to endosialin-expressing cells as well as in eliciting an immune-effector activity particularly on tumor and neovascular cells and precursors. The invention is also related to nucleotides encoding the antibodies of the invention, cells expressing the antibodies; methods of detecting cancer and neovascular cells; and methods of treating cancer and neovascular disease using the antibodies, derivatives and fragments.

The invention relates to a preparation method of a magnetic carbon nanotube surface molecular imprinting material. The preparation method comprises three steps of magnetic carbon nanotube preparation, surface molecular imprinting reaction and template molecule elution. The preparation method has simple processes and can be controlled easily. The magnetic carbon nanotube surface molecular imprinting material obtained by the preparation method has a specific recognition function, excellent magnetic properties, high mechanical strength, a high adsorption capacity and fast binding dynamical properties, can be used as an ideal adsorbent or a coating material used in various solid-phase extraction technologies, can also be used for preparation of molecularly imprinted sensors and chips, and has an important meaning for studying specific recognition and high-sensitivity detection on quinolone drugs.

The invention relates to a preparation method of a magnetic microspheres-based levofloxacin surface imprinted material. The preparation process mainly comprises three steps: preparation of magnetic microspheres; coating of the magnetic microspheres with a molecularly imprinted material; and elution of template molecules. A synthetic method provided by the invention is simple. The prepared magnetic microspheres-based surface molecularly imprinted material has specific recognition function, high adsorption capacity and rapid adsorption ability of levofloxacin and has chiral resolution function of ofloxacin, has good magnetic response and high mechanical strength, can be used as an absorption filler or a coating material, also can be used in preparation of a molecular imprinting sensor and a chip, and is of great significance for researches on specific recognition, chiral resolution and highly sensitive detection of floxacin drugs.

The present invention describes a novel system, drug delivery device, mobile App, drug specific drug dispensing algorithm, and method to improve medication safety and effectiveness via the utilization of drug specific algorithms to control drug dispensing, avoid drug mediated adverse events, ensure prescription persistence and promote prescription compliance on a cost-effective real-time basis.

The invention discloses a kit for detecting a tetracycline drug and a detection method therefor. The kit comprises a microporous reagent and a test paper. The microporous reagent contains freeze-dried colloidal gold-labeled tetracycline drug specific antibodies. The tetracycline drug specific antibodies are tetracycline drug monoclonal antibodies or tetracycline drug polyclonal antibodies. The test paper comprises a sample adsorption pad, a reaction film, a water adsorption pad, a protective film and a base plate, wherein the sample adsorption pad, the reaction film, the water adsorption pad, the protective film and the base plate are connected orderly. The reaction film comprises a detection zone and a quality control zone. The detection zone is coated with a tetracycline hapten-carrier protein conjugate. The quality control zone is coated with antiantibodies. The detection method suitable for the kit has simple processes, realizes fast, visual and accurate detection, has a wide application range and a low cost, and can be used and popularized easily.

With a biconcave disk-shaped red blood cell structure with hemoglobin, a natural cytomembrane and magnetic micro-nano particles as materials, by utilizing the chemical coprecipitation method and the cytomembrane fusion technique to integrate the main constituents of the red blood cell, i.e., the hemoglobin, the magnetic micro-nano particles and the cytomembrane with cellular biological properties,the invention prepares an artificial red blood cell motor with a biconcave disk-shaped red blood cell structure. Compared with the prior art, the invention has the following advantages: the repeatability of the invention is high, the preparation process is simple, and the prepared artificial motor has cell-like biological properties and good stability, and can quickly move along an acoustic pressure gradient under the drive of an exogenous ultrasonic field; moreover, the artificial red blood cell motor can also specifically identify cells (such as cancer cells) by means of the surface-modifying natural cytomembrane, or by applying an exogenous magnetic field, the targeting movement of the artificial red blood cell motor along a movement direction is realized, and the artificial red bloodcell motor has a broad application prospect in the biomedical field, such as oxygen target delivery, specific drug carrying, toxin removal and tumor treatment.

It is intended to provide a drug to be used in gene therapy which specifically targets abnormal cells such as tumor cells and destroys the same for healing. Namely, a drug comprising, as the active ingredient, a proliferative vector which contains a Survivin promoter proliferating depending on the expression of Survivin. This drug may be used in order to treat tumor. In this drug, use may be made of an adenovirus as the vector. In the adenovirus of this drug, an endogenous promoter of an E1A domain may be substituted with a Survivin promoter.

The invention, which belongs to the technical field of medicines, relates to a preparation method for a bio-affinity chromatography column rich in P-glycoprotein and application thereof. A plasma membrane rich in P-glycoprotein is extracted from a Caco-2 cell and, together with an amino-bonded silica gel, forms a P-glycoprotein bio-affinity chromatography column; the constructed P-glycoprotein bio-affinity chromatography column is applied to the chromatographic analysis to verify the specific binding with the drug using the P-glycoprotein as a target; and the P-glycoprotein bio-affinity chromatography column has the specific affinity adsorption function to the P-glycoprotein-positive drug verapamil but has no absorption function to the drug with the non-P-glycoprotein target. Therefore, anovel method is provided for screening the P-glycoprotein target drug. After performance evaluation, the prepared P-glycoprotein bio-affinity chromatography column is demonstrated to have advantages of high specificity and stability and long service life and thus has the broad application prospects.